Biotechnology News and Research

RSS

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Patrys Limited (ASX: PAB), a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Patrys Limited, a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Research: Modification of SUMO protein plays vital role in normal brain function

Scientists are a step closer to understanding how some of the brain's 100 billion nerve cells co-ordinate their communication.

28 Nov 2013

UK to fund over 70 new Centres for Doctoral Training

Details of how a -350 million fund will be used to train over 3,500 postgraduate students in engineering and physical sciences, will be announced today by Universities and Science Minister, David Willetts.

28 Nov 2013

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

A study has shown that a daily probiotic drink changed how cells lining the nasal passages of hay fever sufferers reacted to a single out-of-season challenge. However, it did not lead to significant changes in hay fever symptoms, although this challenge test may not have accurately represented natural allergen exposure.

27 Nov 2013

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.

27 Nov 2013

Edison initiates coverage of biotechnology company focused on adult stem therapies

Edison Investment Research, a leading international investment research firm, announces the initiation of coverage of Mesoblast (MSB: ASX), an Australian-headquartered biotechnology company focused on adult stem therapies.

27 Nov 2013

Customized palliative care can reduce health care costs, improve care for high-risk geriatric patients

For high-risk geriatric patients, improved palliative care that is matched to their changing needs at home can reduce emergency room visits, reduce health care costs, and improve overall care. Current gaps in policy and practice that block implementation of these beneficial customized care models are presented in the article "Research Priorities in Geriatric Palliative Care: Policy Initiatives," published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

27 Nov 2013

Virginia Tech professor named AAAS Fellow for contributions to plant science

John Jelesko, an associate professor of plant pathology, physiology and weed science in the College of Agriculture and Life Sciences at Virginia Tech, has been named a Fellow of the American Association for the Advancement of Science.

26 Nov 2013

Vitamin pills can do more harm than good

Vitamin supplements are a billion-dollar industry. We want to stay healthy and fit and help our bodies with this. But perhaps we are achieving precisely the opposite?

26 Nov 2013

New concept outlines steps to tackle neglected tropical diseases, expedite poverty reduction efforts

A new concept and policy framework published in PLOS NTDs outlines concrete steps for the global development community as it works to synthesize health goals with economic, environmental and social priorities.

26 Nov 2013

Researchers repurpose genetic data, electronic medical records to perform large-scale PheWAS study

Vanderbilt University Medical Center researchers and co-authors from four other U.S. institutions from the Electronic Medical Records and Genomics (eMERGE) Network are repurposing genetic data and electronic medical records to perform the first large-scale phenome-wide association study (PheWAS), released today in Nature Biotechnology.

26 Nov 2013

SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc.

26 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Topokine initiates Phase 2 clinical trial of XAF5 Gel for double chin treatment

Topokine Therapeutics has initiated dosing in a Phase 2, randomized controlled clinical trial of XAF5 Gel for reduction of excess submental fat, commonly known as "double chin." XAF5 Gel is a proprietary skin formulation of a compound already known to reduce fat around the human eye. Study participants are applying XAF5 Gel or placebo once a night to skin under the chin.

20 Nov 2013

University of Wisconsin scientist to present revolutionary stem cell technology to Australian bioindustry

Internationally recognised stem cell scientist, Associate ProfessorIgor Slukvin, University of Wisconsin – Madison, is visiting Australia as the key-note speaker at a Stem Cell Meeting and Workshop in Sydney next week.

19 Nov 2013

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.

18 Nov 2013

Argos Soditic-managed funds announce acquisition of Cisbio Bioassays

The funds managed by Argos Soditic announce the acquisition, together with the management, of Cisbio Bioassays. This cutting-edge biotechnology company is the leader in the field of products and services for human in vitro diagnostics and pharmaceutical research.

18 Nov 2013

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.

18 Nov 2013

New report addresses many changes that transform Medical Education landscape

Medical Education groups are often being transformed by regulatory and budget pressures, making it increasingly difficult to effectively educate healthcare practitioners on the safe and effective use of products. With the pressure to reduce budgets increasing within the pharmaceutical and medical device industries, it is absolutely critical for Medical Education groups to find practical and economical methods of reaching healthcare professionals.

16 Nov 2013

Biotechnology News and Research

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Research: Modification of SUMO protein plays vital role in normal brain function

UK to fund over 70 new Centres for Doctoral Training

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Edison initiates coverage of biotechnology company focused on adult stem therapies

Customized palliative care can reduce health care costs, improve care for high-risk geriatric patients

Virginia Tech professor named AAAS Fellow for contributions to plant science

Vitamin pills can do more harm than good

New concept outlines steps to tackle neglected tropical diseases, expedite poverty reduction efforts

Researchers repurpose genetic data, electronic medical records to perform large-scale PheWAS study

SillaJen executes definitive merger agreement to acquire Jennerex

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Topokine initiates Phase 2 clinical trial of XAF5 Gel for double chin treatment

University of Wisconsin scientist to present revolutionary stem cell technology to Australian bioindustry

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Argos Soditic-managed funds announce acquisition of Cisbio Bioassays

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

New report addresses many changes that transform Medical Education landscape

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News